• SAB Biotherapeutics disclosed a Breakthrough T1D grant backing the PRISE-hATG clinical study of SAB-142 in Stage 3 type 1 diabetes.
• Trial targets patients 100 days to 2 years post-diagnosis, testing whether SAB-142 preserves C-peptide and modulates immune responses.
• Study extends the SAB-142 program alongside the ongoing Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 patients.
• SAB BIO will co-fund PRISE-hATG; no grant amount was disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein.